Comparing Epoetin Delta Dosing in Kidney Disease
Author Information
Author(s): Iain C Macdougall
Primary Institution: King's College Hospital
Hypothesis
Is once weekly dosing of epoetin delta non-inferior to twice weekly and once every two weeks dosing in patients with chronic kidney disease?
Conclusion
The trial aims to determine the best dosing frequency for epoetin delta in managing anaemia in chronic kidney disease patients.
Supporting Evidence
- Anaemia is a common complication of chronic kidney disease.
- Epoetin delta is effective in maintaining haemoglobin levels in anaemic patients.
- The trial will help guide appropriate dosing frequency for epoetin delta.
Takeaway
This study is trying to find out how often patients with kidney disease should take a medicine called epoetin delta to help with their anaemia.
Methodology
This is a randomized, open-label, multicentre trial involving patients aged 18 and above with chronic kidney disease, comparing different dosing regimens of epoetin delta.
Potential Biases
Potential bias in patient selection and reporting of outcomes.
Limitations
The study may not account for all variables affecting anaemia management in chronic kidney disease.
Participant Demographics
Patients aged 18 years or older with chronic kidney disease (Stages 3–5).
Statistical Information
Confidence Interval
95% CI for the difference between dosing regimens.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website